-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
COVID-19 is a major epidemic facing the world today, which has an impact on current microbiota-based treatments.
COVID-19 infection
In addition, the article emphasizes that there is an urgent need to investigate the possible impact of COVID-19 on the safety and effectiveness of FMT, as well as the establishment of strict donor and recipient screening protocols during and after the COVID-19 pandemic to produce optimization FMT treatment plan.
There are four possible combinations and conditions for FMT during the COVID-19 pandemic and after the COVID-19 pandemic: (1) Asymptomatic COVID-19 donor and asymptomatic COVID-19 recipient; (2) Asymptomatic COVID- 19 donors and COVID-19 negative recipients; (3) COVID-19 negative donors and asymptomatic recipients; (4) COVID-19 negative donors and COVID-19 negative recipients.
FMT donors should be healthy and have no known gastrointestinal disease or recent antibiotic treatment (within 90 days).
Antibiotic Immune Metabolic Syndrome During and after the COVID-19 pandemic, it is more important than ever to develop a more consistent and evidence-based FMT screening program.
As the COVID-19 pandemic spreads globally, it is urgent to take preventive measures to screen FMT donors for SARS-CoV-2 to prevent the potential risk of the spread of COVID-19.
FDA recommends that only FMT products produced from feces donated before December 1, 2019 can be used until appropriate testing and screening programs are obtained.
COVID-19 and FMT efficacy
As we all know, the intestinal microflora plays a vital role in human metabolism, immunity and disease.
Since the beginning of the pandemic, the gut-pulmonary axis has produced a large number of reports.
Previous studies have shown that more than 60% of patients with new coronary pneumonia have gastrointestinal symptoms and report evidence of gastrointestinal symptoms, such as diarrhea, nausea and vomiting.
The formation of single-chain fatty acids is due to the fact that the fermentation of complex carbohydrates affects a series of host processes, including host-microbial signaling, energy utilization and colon pH control, thereby affecting the composition of microflora and intestinal motility.
The role of biological therapy may be an important tool for controlling the excessive inflammation of new coronary pneumonia and reducing the incidence, duration and severity of viral respiratory infections.
A study conducted in Wuhan, China investigated the relationship between the composition of the intestinal flora and the susceptibility of healthy people to SARS-CoV-2.
It is very important to clarify the role of intestinal microflora and intestinal-pulmonary axis in respiratory diseases to reveal their role in the treatment of new coronary pneumonia , and to clarify the role of intestinal microflora and intestinal-pulmonary axis in respiratory diseases To reveal their role in the treatment of new coronary pneumonia is very important.
Original source
Kazemian N, Kao D, Pakpour S.
Kazemian N, Kao D, Pakpour S.
Leave a message here
